NASDAQ:MDVN - Medivation Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous Close$81.44
Today's Range$81.44 - $81.44
52-Week Range$26.41 - $81.48
VolumeN/A
Average Volume3.55 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Medivation, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company, in collaboration with Astellas Pharma, Inc. (Astellas), has one commercial product, XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States, Europe and other countries across the world for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company, in collaboration with Astellas, is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. It has developed a small molecule inhibitor of the sterol regulatory element-binding protein, or SREBP, pathway which it refers to as MDV4463.

Receive MDVN News and Ratings via Email

Sign-up to receive the latest news and ratings for MDVN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryBiotechnology
SectorN/A
Current SymbolNASDAQ:MDVN
CUSIP58501N10
Phone+1-415-5433470

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Medivation (NASDAQ:MDVN) Frequently Asked Questions

What is Medivation's stock symbol?

Medivation trades on the NASDAQ under the ticker symbol "MDVN."

How were Medivation's earnings last quarter?

Medivation Inc (NASDAQ:MDVN) issued its earnings results on Tuesday, August, 9th. The biopharmaceutical company reported $0.29 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.27 by $0.02. The biopharmaceutical company earned $206 million during the quarter, compared to analyst estimates of $214.52 million. Medivation's quarterly revenue was up 17.4% on a year-over-year basis. During the same period in the prior year, the business earned $0.58 earnings per share. View Medivation's Earnings History.

Has Medivation been receiving favorable news coverage?

Headlines about MDVN stock have trended somewhat negative on Thursday, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Medivation earned a media sentiment score of -1.0 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future.

What other stocks do shareholders of Medivation own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medivation investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), United Continental (UAL), Dynavax Technologies (DVAX), Kite Pharma (KITE), Array Biopharma (Arry), Freeport-McMoRan (FCX) and Celgene (CELG).

How do I buy shares of Medivation?

Shares of MDVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Medivation's official website?

The official website for Medivation is http://www.medivation.com/.

How can I contact Medivation?

Medivation's mailing address is 525 Market St Fl 36, SAN FRANCISCO, CA 94105-2747, United States. The biopharmaceutical company can be reached via phone at +1-415-5433470.


MarketBeat Community Rating for Medivation (NASDAQ MDVN)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  705 (Vote Outperform)
Underperform Votes:  440 (Vote Underperform)
Total Votes:  1,145
MarketBeat's community ratings are surveys of what our community members think about Medivation and other stocks. Vote "Outperform" if you believe MDVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDVN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/25/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel